Skip to main content
Clinical Trials/DRKS00029126
DRKS00029126
Recruiting
Not Applicable

Systematic retrospective evaluation of patients with sarcoidosis treated with the Havelhöher Sarcoidosis Therapy Protocol (HSP)

Wala Heilmittel GmbH Pharmakologische und klinische Forschung0 sites150 target enrollmentJuly 8, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
D86.9
Sponsor
Wala Heilmittel GmbH Pharmakologische und klinische Forschung
Enrollment
150
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 8, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Wala Heilmittel GmbH Pharmakologische und klinische Forschung

Eligibility Criteria

Inclusion Criteria

  • 1\) Clinically and/or histologically confirmed diagnosis of sarcoidosis in the years 2005 to 2020\.
  • 2\) Treatment with HSP
  • 3\) Documentation of therapy in the Turbomed database of the outpatient clinic or in Clinixx\- documentation of the pulmonary department of the gemeinschaftskrankenhaus Havelhoehe
  • 4\) Age at least 18 years
  • 5\) Legal capacity
  • 6\) Voluntary and written informed consent before the start of the study.

Exclusion Criteria

  • 1\) Clinically relevant concomitant conditions that unduly limit the assessment of efficacy and tolerability. These include:
  • \- confirmed autoimmune diseases
  • \- active tumor diseases
  • \- acute sarcoidosis (Löfgren's syndrome)
  • \- treatment with less than 1 cycle of HSP
  • \- incomplete data set (i.e., less than 2 radiographs during the course, less than 2 clinically defined measurement parameters documented below 80%)

Outcomes

Primary Outcomes

Not specified

Similar Trials